Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
A phase 3 trial of Imatinib in chronic myeloid leukaemia, run by Il-Yang Pharm. Co., Ltd., active and no longer recruiting.
Overview
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) is a phase 3 interventional study registered as NCT03722420 by Il-Yang Pharm. Co., Ltd., with 238 participants enrolled, started 2018-12-28 and due to reach its primary completion in 2023-03-03. Interventions recorded: Radotinib and Imatinib.
Similar pages
not linked directly; found by shared links- TrialA Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialA Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialA Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Shares Chronic myeloid leukaemia (CML), Imatinib and the tag pipeline.
- TrialTGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialThe Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialAsciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
- TrialOpen-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.